BioSpace News Archive

Antibe Therapeutics Inc., a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 - 15.

Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2021 on Wednesday, October 27, 2021. During a conference call at 8 a.m. ET on October 27, 2021, company executives will review financial results and address inquiries from investors and analysts.

ReForm Biologics , Inc. today announced the appointment of Jeffrey S. Hackman as President and Chief Executive Officer (CEO).

Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers

Appili Therapeutics Inc. today announced the results from its annual general meeting of shareholders held on Tuesday, September 7, 2021.

Gain Therapeutics, Inc., a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, announced topline data from the Company’s study, conducted at the University of Maryland School of Medicine.

Monte Rosa Therapeutics, Inc. today announced that Markus Warmuth, M.D., Chief Executive Officer, and Ajim Tamboli, CFA, Chief Financial Officer, are scheduled to participate in a virtual fireside chat at 2 p.m. ET on Wednesday, Sept. 15 at the Morgan Stanley 19th Annual Global Healthcare Conference.

MiMedx Group, Inc. today announced the shelf registration statement on Form S-3 on file with the Securities and Exchange Commission (SEC) has become effective.

Bolt Biotherapeutics, Inc. today announced that it has entered into a clinical collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to investigate Bolt Biotherapeutics’ BDC-1001 in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor Opdivo® (nivolumab).

Premier Inc . (NASDAQ: PINC), a leading technology-driven healthcare improvement company, and 11 leading health systems acquired a minority stake in Exela Holdings, Inc. to secure vital supply of pharmaceutical products and support domestic production.